Abstract
The serotonin transporter gene promoter polymorphism (5-HTTLPR) has been repeatedly associated with antidepressant response in mood disorder patients, but findings are not consistent across studies. A meta-analysis was performed on 15 studies including data of 1435 subjects. We tested three phenotypes: remission rate, response rate and response rate within 4 weeks using the cochrane review manager. We observed a significant association of the s/s variant of 5-HTTLPR with remission rate (P<0.0001) and both s/s and s/l variants with response rate (P=0.0002). Response rate within 4 weeks was associated in both models (P=0.003–P<0.00001). This effect is quite robust to ethnic differences although a significant heterogeneity is present in Asian samples.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER . The economic burden of depression in 1990. J Clin Psychiatry 1993; 54: 405–418.
Sartorius N . The economic and social burden of depression. J Clin Psychiatry 2001; 62(Suppl 15): 8–11.
Wittchen H-U, Jacobi F . Size and burden of mental disorders in Europe – a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005; 15: 357–376.
Ustun TB . The worldwide burden of depression in the 21st century. In: Weismann MM (ed). Treatment of Depression: Bridging the 21st Century. American Psichiatric Press: Washington, DC, 2001, pp 35–45.
Fava M, Davidson KG . Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996; 19: 179–200.
Fava M . Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003; 53: 649–659.
Heils A, Teufel A, Petri S, Stöber G, Riederer P, Bengel D et al. Allelic variation of human serotonin trasporter gene expression. J Neurochem 1996; 66: 2621–2624.
Serretti A, Calati R, Mandelli L, De Ronchi D . Serotonin transporter gene variants and behaviour: a comprehensive review. Current Drug Targets, in press.
Smeraldi E, Zanardi R, Benedetti F, Dibella D, Perez J, Catalano M . Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3: 508–511.
Serretti A, Artioli P, Quartesan R . Pharmacogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenet Genom 2005; 15: 61–67.
Smits KM, Smits LJ, Schouten JS, Stelma FF, Nelemans P, Prins MH . Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry 2004; 9: 433–441.
Munafo MR, Flint J . Meta-analysis of genetic association studies. Trends Genet 2004; 20: 439–444.
Cho HJ, Meira-Lima I, Cordeiro Q, Michelon L, Sham P, Vallada H et al. Population-based and family-based studies on the serotonin transporter gene polymorphisms and bipolar disorder: a systematic review and meta-analysis. Mol Psychiatry 2005; 12: 12.
Lasky-Su JA, Faraone SV, Glatt SJ, Tsuang MT . Meta-analysis of the association between two polymorphisms in the serotonin transporter gene and affective disorders. Am J Med Genet B Neuropsychiatr Genet 2005; 133: 110–115.
Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L . 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol 2003; 23: 563–567.
Hong CJ, Chen TJ, Yu YW, Tsai SJ . Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenom J 2006; 6: 27–33.
Joyce PR, Mulder RT, Luty SE, McKenzie JM, Miller AL, Rogers GR et al. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol 2003; 6: 339–346.
Kato M, Fukuda T, Wakeno M, Fukuda K, Okugawa G, Ikenaga Y et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiol 2006; 53: 186–195.
Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000; 11: 215–219.
Kirchheiner J, Nickchen K, Sasse J, Bauer M, Roots I, Brockmoller J . A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacogenom J 2006.
Serretti A, Artioli P . The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenom J 2004; 4: 233–244.
Yoshida K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 383–386.
Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ . Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002; 7: 1115–1119.
Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E . Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 2000; 20: 105–107.
Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 2001; 50: 323–330.
Quitkin FM, Rabkin JG, Ross D, Stewart JW . Identification of true drug response to antidepressants. Use of pattern analysis. Arch Gen Psychiatry 1984; 41: 782–786.
Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB . The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berlin) 2004; 174: 525–529.
Kraft JB, Slager SL, McGrath PJ, Hamilton SP . Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry 2005; 58: 374–381.
Lee MS, Lee HY, Lee HJ, Ryu SH . Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatr Genet 2004; 14: 111–115.
Minov C, Baghai TC, Schule C, Zwanzger P, Schwarz MJ, Zill P et al. Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett 2001; 303: 119–122.
Murphy Jr GM, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF . Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004; 61: 1163–1169.
Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23: 587–590.
Rausch JL, Johnson ME, Fei YJ, Li JQ, Shendarkar N, Hobby HM et al. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry 2002; 51: 723–732.
Lesch KP . Variation of serotonergic gene expression: neurodevelopment and the complexity of response to psychopharmacologic drugs. Eur Neuropsychopharmacol 2001; 11: 457–474.
Hranilovic D, Stefulj J, Schwab S, Borrmann-Hassenbach M, Albus M, Jernej B et al. Serotonin transporter promoter and intron 2 polymorphisms: relationship between allelic variants and gene expression. Biol Psychiatry 2004; 55: 1090–1094.
Greenberg BD, Tolliver TJ, Huang SJ, Li Q, Bengel D, Murphy DL . Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet 1999; 88: 83–87.
Javors MA, Seneviratne C, Roache JD, Ait-Daoud N, Bergeson SE, Walss-Bass MC et al. Platelet serotonin uptake and paroxetine binding among allelic genotypes of the serotonin transporter in alcoholics. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 7–13.
Teshima KM, Przeworski M . Directional positive selection on an allele of arbitrary dominance. Genetics 2006; 172: 713–718.
Williams NM, O'Donovan MC, Owen MJ . Is the dysbindin gene (DTNBP1) a susceptibility gene for schizophrenia? Schizophr Bull 2005; 31: 800–805.
Allison DB . Transmission-disequilibrium tests for quantitative traits. Am J Hum Genet 1997; 60: 676–690.
Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP . Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004; 9: 879–889.
Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 2006; 78: 815–826.
Nakamura M, Ueno S, Sano A, Tanabe H . The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry 2000; 5: 32–38.
Smeraldi E, Serretti A, Artioli P, Lorenzi C, Catalano M . Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variants. Psychiatr Genet 2006; 16: 153–158.
Kunugi H, Hattori M, Kato T, Tatsumi M, Sakai T, Sasaki T et al. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol Psychiatry 1997; 2: 457–462.
Kato M, Ikenaga Y, Wakeno M, Okugawa G, Nobuhara K, Fukuda T et al. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol 2005; 20: 151–156.
Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9: 442–473.
Kendler KS . ‘A gene for …’: the nature of gene action in psychiatric disorders. Am J Psychiatry 2005; 162: 1243–1252.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Serretti, A., Kato, M., De Ronchi, D. et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 12, 247–257 (2007). https://doi.org/10.1038/sj.mp.4001926
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.mp.4001926
Keywords
This article is cited by
-
Novel Antidepressant-Like Properties of the Iron Chelator Deferiprone in a Mouse Model of Depression
Neurotherapeutics (2022)
-
Serotonergic gene-to-gene interaction is associated with mood and GABA concentrations but not with pain-related cerebral processing in fibromyalgia subjects and healthy controls
Molecular Brain (2021)
-
Economic evaluation in psychiatric pharmacogenomics: a systematic review
The Pharmacogenomics Journal (2021)
-
Association between functional polymorphisms in serotonin transporter gene (SLC6A4) and escitalopram treatment response in depressive patients in a South Indian population
European Journal of Clinical Pharmacology (2020)
-
BDNF Val66Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizoaffective disorder patients: a meta-analysis
The Pharmacogenomics Journal (2019)